Revolution Medicines Inc. (RVMD) News

Revolution Medicines Inc. (RVMD): $36.44

0.38 (-1.03%)

POWR Rating

Component Grades








Add RVMD to Watchlist
Sign Up

Industry: Biotech




#266 of 363

in industry

Filter RVMD News Items

RVMD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RVMD News Highlights

  • For RVMD, its 30 day story count is now at 3.
  • Over the past 11 days, the trend for RVMD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DRUG and SAFE are the most mentioned tickers in articles about RVMD.

Latest RVMD News From Around the Web

Below are the latest news stories about REVOLUTION MEDICINES INC that investors may wish to consider to help them evaluate RVMD as an investment opportunity.

Revolution Medicines Inc Insider Sells Shares

Margaret Horn, COO of Revolution Medicines Inc (NASDAQ:RVMD), sold 7,993 shares of the company on December 18, 2023, according to a recent SEC Filing.

Yahoo | December 21, 2023

Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development

These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.

John Blankenhorn on InvestorPlace | December 15, 2023

Insider Sell Alert: COO Margaret Horn Sells 5,000 Shares of Revolution Medicines Inc (RVMD)

In the realm of biopharmaceuticals, insider transactions are often scrutinized for insights into the company's health and future prospects.

Yahoo | December 10, 2023

A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who own 74% must be happy

Key Insights Given the large stake in the stock by institutions, Revolution Medicines' stock price might be vulnerable...

Yahoo | November 17, 2023

3 Biotech Stocks That Could Boom or Bust by 2025

Biotech stocks are popular with investors because they sometimes provide tremendous rewards.

Will Ashworth on InvestorPlace | November 16, 2023

Revolution Medicines Completes Acquisition of EQRx

Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs Sandra Horning, M.D., Joins Revolution Medicines' Board of Directors REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc

Yahoo | November 9, 2023

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

Transaction on Track to Close in November 2023REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. (Nasdaq: EQRX), announced that earlier today, at their respective special meetings, Revolution Medicines and EQRx stockholders voted to approve Revolution Medicines’ proposed acquisition of EQRx. The final votes will be certified

Yahoo | November 8, 2023

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be […]

Yahoo | November 7, 2023

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 1.98% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 6, 2023

Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress

Company's cash position improves while R&D expenses rise due to increased clinical trial and manufacturing expenses

Yahoo | November 6, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!